Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).

Nyxoah's mission is to become a world leading company by offering unique patient-centric neuromodulation solutions.

Nyxoah was founded in 2009 by Robert Taub. The company is headquartered in Mont-Saint-Guibert, Belgium.


Nyxoah’s lead solution platform is based on the Genio® system, a validated, user-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.


Nyxoah’s therapy consists of a tiny neurostimulator implanted in the chin area in a discrete and minimally invasive surgery. The system which is powered by an external miniaturized battery is placed under the chin and stimulates the tongue nerve. This maintains the upper airway open throughout the night.


Nyxoah is backed by Cochlear Investments Pty Ltd, ResMed, Robert Taub (Founder and Chairman of Nyxoah), and others. The company raised €13.35M ($15M) in private placement financing on Mar 23, 2023. This brings Nyxoah's total funding to €79.4M to date.



  • Year founded: 2009
  • Funding Info: €79.4M over 5 Rounds (Latest Funding Type: Corporate Round)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Mont-Saint-Guibert
  • State: Walloon Brabant
  • Country: Belgium
Related businesses